CD274 and esophageal squamous cell carcinoma: However, the JUPITER-06 and ORIENT-15 trials indicated that sintilimab or toripalimab plus chemotherapy could improve survival benefits of ESCC patients with low PD-L1 expression (CPS<10) compared to chemotherapy.